Clinical Trial Update: Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating anti-CD19 CAR-T cells for relapsed/refractory CD19+ malignancies; the trial is currently recruiting at the University of Utah and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: University of Utah | Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma | Phase 1 | Status: RECRUITING